Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Friday, November 4, 2022
Using the anti-SLAMF7 antibody to shield SLAM57 antigens on T cells may help the manufacturing of SLAMF7 chimeric antigen receptor (CAR) T cells for adoptive therapy for multiple myeloma, according to findings presented at the 2022 International Myeloma Society (IMS) Annual Meeting and Exposition (Abstract OAB-059). The prevention of these antigens may lead to an increased yield, augmented phenotype, and antimyeloma function in preclinical models, concluded Sabrina R. Prommersberger, PhD, of the Universitätsklinikum Würzburg, Germany, and colleagues.
“The anti-SLAMF7 antibody is available in pharmaceutical grade and [can] be seamlessly incorporated into cGMP manufacturing processes for the next generation of trials under the CARAMBA [investigative new drug],” the authors said.
In this ongoing phase I/IIa trial, the authors generated SLAMF7 CAR T cells by using the cGMP-compliant manufacturing protocol in the ongoing phase I/IIA CARAMBA trial. The investigators added different concentrations of anti-SLAMF7 antibodies to the culture medium after SLAMF7 CAR gene transfer.
At the end of the manufacturing campaign, the total expansion factor of T cells treated with anti-SLAMF7 antibody was 9.3, compared with 2.0 in the conventional process. In addition, the authors reported, using anti-SLAMF7 antibodies had the strongest effect immediately after gene transfer because of a higher proportion of viable T cells.
Of note, the authors added, was a strong antimyeloma efficacy of SLAMF7 CAR T cells that had been treated with an anti-SLAMF7 antibody. In particular, there was a greater proliferation of SLAMF7 CAR T cells after stimulation with multiple myeloma target cell lines, which the authors believe indicates improved T-cell fitness.
Disclosure: Study authors’ disclosure information was not provided.
2022 IMS Annual Meeting and Exposition
JNCCN Spotlights
